Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...
Oppenheimer Asset Management Inc. Decreases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Oppenheimer Asset Management Inc. decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 8.5% during the fourth quarter, HoldingsChannel.com reports. The ...
Zacks Investment Research on MSN7d
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks ...
StockStory.org on MSN7d
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced in Q4 CY2024, with sales up 65.9% year on year to $658.4 million ...
Sarepta files automatic mixed securities shelf
EST Sarepta (SRPT) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $161.00 at Royal Bank of Canada
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...
Sarepta price target lowered to $210 from $217 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $210 from $217 and keeps a Buy rating on the shares. Management is confident in FY25 ...
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to ...
Benzinga.com7d
8 Analysts Have This To Say About Sarepta Therapeutics
In the last three months, 8 analysts have published ratings on Sarepta Therapeutics SRPT, offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view ...
Morningstar6d
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne Sarepta Therapeutics, Inc. (NASDAQ ...